Telangiectasis
13
0
0
9
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 13 trials
100.0%
+13.5% vs benchmark
38%
5 trials in Phase 3/4
33%
3 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 9 completed trials
Clinical Trials (13)
The Effect of 16-week Dietary Intake of Food Supplements Containing Collagen and MSM on Facial Erythema and Other Skin Parameters
Effect of Avastin in Juxtafoveal Telangiectasias
Lower Limb Sclerotherapy of Reticular Veins and Telangiectasias
Polidocanol Versus Glucose Treatment of Telangiectasia Trial
Laser Therapy Versus Electrosurgery For Nasal Telangiectasias
Epidemiology of Venous Disease
Biobehavioral Determinants of Obesity in Black Women
Comparison Between Two Different Parameters of Argon Plasma Coagulation in the Treatment of Chronic Radiation Proctitis: Historical Control Trial.
High-Dose Lucentis (Ranibizumab 2.0mg) for the Treatment of Nonproliferative Idiopathic Parafoveal Telangiectasia
Treatment of Lower Extremity Spider Veins With Excel V
Trial of Endoscopy Bipolar and Argon of Chronic Rectal Bleeding From Radiation Telangiectasias
Intravitreal Bevacizumab for Idiopathic Macular Telangiectasia
Pulsed Dye Laser and Intense Pulsed Light (IPL) for the Treatment of Telangiectasia and Skin Redness